WuXi AppTec
2025.07.16
17:13
JPMorgan's short position in WuXi AppTec (02359.HK) increased from 4.13% to 4.71% on July 11, and its long position increased from 7.35% to 9.24%.
2025.07.11
16:10
At the close of Hong Kong stocks, the Hang Seng Index closed up 0.46% and the Hang Seng Technology Index closed up 0.61%. Chinese brokerage stocks strengthened, with Zhongzhou Securities (01375.HK) closing up 47%; biopharmaceutical concepts rebounded sharply, with WuXi AppTec (02359.HK) closing up 10%; chip, insurance, cryptocurrency and other concepts led the gains.
12:15
Nomura: WuXi AppTec may raise its annual revenue forecast, maintain its buy rating and raise its target price from HK$84.59 to HK$102.77.
12:01
Hong Kong Stock Midday Review: Hang Seng Index rose 1.90% and Hang Seng Technology Index rose 2.08%
At the close of Hong Kong stocks at noon, the Hang Seng Index rose 1.90%, and the Hang Seng Technology Index rose 2.08%. The Hong Kong Stock Technology ETF (159751) rose 1.17%, and the Hang Seng Hong Kong Stock Connect ETF (159318) rose 1.22%. WuXi AppTec rose more than 11%, NIO rose more than 7%, WuXi Biologics rose more than 6%, and Ping An of China rose more than 5%.
10:45
Nomura raised its target price for WuXi AppTec from HK$84.59 to HK$102.77
Nomura raised its target price for WuXi AppTec from HK$84.59 to HK$102.77.
10:22
CRO concept stocks rose again, WuXi AppTec hit the daily limit
CRO concept stocks rose again, WuXi AppTec hit the daily limit, Boten shares hit the 20cm daily limit, Medicilon rose more than 10%, and Alethe and Corning Life Sciences led the gains. WuXi AppTec expects its adjusted net profit for the first half of 2025 to be approximately RMB 6.315 billion, a year-on-year increase of approximately 44.43%.
09:39
Hong Kong stocks of innovative drug stocks strengthened sharply in early trading. WuXi AppTec (02359.HK) reported a profit warning and rose more than 10%, WuXi Hepharm (02268.HK) rose more than 7%, and stocks such as Boan Biopharm (06955.HK) and Hengrui Medicine (01276.HK) followed suit.
09:35
Hong Kong stocks CXO concept stocks rose in early trading, and Kaleo rose more than 10%
Hong Kong-listed CXO concept stocks rose in early trading, with CStone Pharmaceuticals up more than 10%, WuXi AppTec up more than 9%, Zhaoyan Pharmaceutical up more than 7%, Corning Life Sciences and WuXi Biologics up more than 4%.
09:22
When the Hong Kong stock market opened, the Hang Seng Index opened up 0.02%, and the Hang Seng Technology Index opened down 0.28%; the concept of cryptocurrency has been strong for several days, and the concept of innovative drugs has rebounded; Zhixing Technology (01274.HK) received a designation letter for 5 models from a leading independent brand, up more than 14%; OKEx (01499.HK) rose more than 6%; WuXi AppTec (02359.HK) reported a profit warning and rose 4.8%.
09:21
Hong Kong stocks opened: Hang Seng Index opened 0.02% higher, Hang Seng Technology Index opened 0.28% lower
Hong Kong stocks opened, the Hang Seng Index opened 0.02% higher, and the Hang Seng Technology Index opened 0.28% lower. WuXi AppTec opened 4.8% higher. The company expects to achieve an adjusted net profit of approximately RMB 6.315 billion in the first half of 2025, a year-on-year increase of approximately 44.43%.
2025.07.10
18:17
WuXi AppTec: Expected adjusted net profit for the first half of 2025 to be approximately RMB 6.315 billion, a year-on-year increase of approximately 44.43%
WuXi AppTec announced that the company expects to achieve operating income of approximately RMB 20.799 billion in the first half of 2025, an increase of approximately 20.64% year-on-year, of which the income from continuing operations increased by approximately 24.24% year-on-year. It is expected that the adjusted net profit attributable to the company's shareholders under the International Financial Reporting Standards will be approximately RMB 6.315 billion in this period, an increase of approximately 44.43% year-on-year. It is expected that the net profit attributable to the company's shareholders after deducting non-recurring gains and losses will be approximately RMB 5.582 billion in this period, an increase of approximately 26.47% year-on-year, which is mainly affected by exchange rate fluctuations compared with the adjusted net profit attributable to the parent company. It is expected that the net profit attributable to the company's shareholders will be approximately RMB 8.561 billion in this period, an increase of approximately 101.92% year-on-year, which includes investment income from the sale of part of the equity of the associated company; the basic earnings per share for this period is expected to be approximately RMB 3.01 per share, an increase of approximately 106.16% year-on-year.
2025.07.08
17:18
Hong Kong Stock Exchange documents show that BlackRock's (BLK.N) holdings in WuXi AppTec's (02359.HK) H shares fell to 4.98% from 5.49% on July 2.
2025.07.07
11:27
Hong Kong stocks CXO concept stocks fluctuated downward, WuXi Biologics fell more than 5%
CXO concept stocks in Hong Kong stocks fluctuated downward, with WuXi Biologics falling more than 5%, GenScript Biotech falling more than 3%, and CStone Pharmaceuticals, WuXi AppTec, Tigermed, and Zhaoyan Pharmaceutical falling more than 2%.
10:14
Hong Kong stocks with biopharmaceutical concepts led the decline in early trading, with Rongchang Biopharma (09995.HK) falling more than 5%, WuXi Biologics (02268.HK) and WuXi Biologics (02269.HK) both falling more than 4%, and InnoCare Pharma (09969.HK), WuXi AppTec (02359.HK) and other stocks following the decline; on the news front, the U.S. "Big Beautiful Act" was passed early this morning, the bill proposes to cut healthcare spending.
2025.06.30
18:24
WuXi AppTec: Plan Trustee Completes HK$1 Billion Purchase of H Shares under Additional Grant Conditions of 2025 H Share Incentive Trust Plan
WuXi AppTec announced that the plan trustee, in accordance with the company's instructions, has implemented the purchase of H shares under the additional grant conditions of the 2025 H-Share Incentive Trust Plan through on-market transactions, using a total of HK$1 billion to purchase 12.9879 million H shares, accounting for approximately 0.45% of the company's total issued share capital as of the date of this announcement. The H shares purchased this time will be used as the source of shares for granting awards to selected participants after the additional grant conditions under the 2025 H-Share Incentive Trust Plan (i.e. the Group's operating income in 2025 reaches RMB43 billion or more) are met. As of the date of this announcement, the plan trustee has completed the purchase of H shares under the 2025 H-Share Incentive Trust Plan for a total of HK$2.5 billion, which will be used as the source of shares for granting awards under the basic grant conditions and additional grant conditions.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Oppenheimer: Raises Nvidia (NVDA.O) price target from $175 to $200.

2025-07-15

Shanghai: Accelerate the implementation of major engineering projects and build core capabilities of the smart glasses industry

2025-07-15

ETF Midday Review: ChiNext Artificial Intelligence ETF Southern led the gains by 4.95%, while the CSI 2000 ETF Fund led the losses by 4.36%

2025-07-15

Tesla Model Y long-range rear-wheel drive version is priced at about RMB 567,000 in India

2025-07-15

BOE A: Will submit a review to the ITC regarding the preliminary ruling of the 337 investigation on trade secrets

2025-07-15

ASIA TECH WIRE

Grasp technology trends

Download